Aptargroup Inc (ATR) 2020 Q4 法說會逐字稿

Ladies and gentlemen, thank you for standing by. Welcome to Aptar's 2020 Fourth Quarter Conference Call. (Operator Instructions)

Introducing today's conference call is Mr. Matt DellaMaria, Senior Vice President, Investor Relations and Communications. Please go ahead, sir.

Thank you. I'd like to welcome everyone joining us on the call today and everyone listening to the webcast. Joining me on today's call are Stephan Tanda, President and CEO; and Bob Kuhn, Executive Vice President and CFO.

Our press release and accompanying slide deck have been posted to our website. If you are following along on the website, you can advance the slides by hovering over the presentation screen and clicking on the arrows on the right and on the left. As always, we will post a replay of this call on the website.

Today's call includes some forward-looking statements. Please refer to our SEC filings to review factors that could cause actual results to differ materially from what we are discussing today.

I would now like to turn the conference call over to Stephan.

Thank you, Matt, and good morning, everyone. We appreciate you joining us today. I hope that you and your families are staying healthy and safe.

Before we turn the page on 2020, I would like to take a moment to speak to Slide 3 and recognize our people for their tremendous commitment to deliver on the promises we made to our customers, patients, consumers and business partners. I want to thank our teams for facing the challenges presented throughout the year with unwavering strength and resilience and for living up to our purpose and responsibility to society, namely to ensure that our innovative solutions are readily available to dispense critical medicines and consumer products to millions of people each day. At Aptar, we are focused on transforming ideas into products that improve everyday lives, and we are proud of the company's vital role in society. We are well positioned to continue to invest and grow in 2021.

Turning now to Slide 4. Aptar is a steady, long-term compounding growth story, and that is how we manage the business: for growth over the next 5 to 10 years and well beyond. In 2020, we continued our strong total shareholder return journey, and our shareholders achieved 102% total shareholder return, or TSR, over the past 5 years. Our diversified business proved to be resilient to the significant economic and pandemic challenges and helped us overcome temporary weaknesses in certain markets, mainly the beauty market. We also made strategic investments during the year that will add critical capacity to key areas such as lotion pumps and components for injected medicines. And we were active on the M&A front, acquiring FusionPKG to bolster our go-to-market turnkey capabilities. In addition, we invested in selected partners such as Sonmol. We're developing connected health care solutions to further strengthen our portfolio.

Looking at our performance for the year, our reported sales increased 2%, and on a comparative basis, core sales were in line with the prior year. I am pleased that we achieved record cash flow from operations and record free cash flow through the combination of the strong performance of our Pharma segment, contributions from recent cash accretive acquisitions, cost containment efforts and working capital improvements. Further, our balance sheet remains in excellent condition, and we are well positioned to continue to pursue strategic M&A opportunities. Another key element of our compounding growth story is our dividend program, and I'm happy to report that in 2020, we returned $93 million to shareholders. This was our 27th consecutive year of paying an increased dividend.

I will briefly comment on our Q4 results, as shown on Slide 5, before turning it over to Bob, who will go into a bit more detail. Our teams delivered a strong finish to the year with fourth quarter core sales growth of 5% and recent acquisitions adding 3% on top of that. Broad-based demand for our industry-leading drug-delivery devices and for our food dispensing closures drove double-digit core sales increases in our Pharma and Food + Beverage segments.

In our Pharma segment, I am pleased with the diverse growth across our Pharma divisions as we continue to supply critical devices for everyday medicines while we further engage with customers with more urgent needs related to fighting the pandemic. In our Food + Beverage segment, steady strong demand for food closures and some restocking by certain beverage customers helped in the quarter.

Our Beauty + Home segment continues to make top line progress and would have posted positive core sales growth had it not been for lower custom tooling sales compared to the prior year. We achieved double-digit core growth in our personal care and home care applications on strong demand for our dispensing systems used for sanitizers and cleaners. We also saw a gradual improvement in the beauty fragrance market, though sales were still considerably behind the prior year. The decline in the fragrance business was partially offset by increased sales of dispensers for facial skin care products.

We have successfully implemented the vast majority of our plant initiatives related to our transformation over the past 3 years, including implementing new commercial strategies, reducing costs and adding capabilities in Asia and in fast-growing application fields that we believe will position the segment for future growth and expanded profitability. However, the 2020 COVID-19 global pandemic has caused several initiatives that were expected to be completed by the end of the year to be somewhat delayed, including the planned closure of 2 facilities in the U.S. and resulted in a significant decline in our Beauty business. While our Beauty + Home segment continues to be profitable, the disruption caused by the pandemic, including higher operating costs, have more than offset any expected growth in earnings from our transformation. We remain committed to completing our remaining transformation initiatives and expect the return to growth to be gradual and nonlinear as this market is highly correlated to the return of post-pandemic normal consumer behavior, including travel, which to date has proven to be sporadic and uncertain.

We continue to invest in research and development efforts that support our growing patent portfolio of over 5,000 active patents. Our examples of recent technology and innovation solutions are found on Slide 6. And I would like to highlight just a few of them.

In Pharma, we announced this week that our 3-Phase Activ-Film technology was chosen to protect a new SARS rapid antigen test for COVID-19 that recently received Emergency Use Authorization from the U.S. FDA. The QuickVue SARS Antigen test is a point-of-care rapid antigen test developed by Quidel Corporation that delivers test results in 10 minutes. The visually read test requires no supplemental instrumentation and offers expanded access to affordable and accurate COVID-19 testing that will help meet the urgent testing needs in those in school systems and rural areas. In the injectables market, we have a supply position on several of the leading COVID-19 vaccines and treatments in selected parts of the world. In the consumer health care market, we helped P&G extend the Vicks VapoCOOL portfolio with our nasal spray device that delivers an ultrafine mist for their new VapoCOOL sinus congestion and pressure release product.

In Beauty + Home, we have helped a company called Lightinderm in France to launch a home-use skin care device with infrared regenerative light with photoactive-packed serums to provide skin rejuvenation and regeneration. Aptar provided the airless piston system and reloadable recyclable capsules. Our airless technology is also featured on L'Oréal's Kiehl's brand Hydro-Plumping Hydrating Serum and was customized for an eye cream in China by the brand Infinitus. This technology comes in a wide range of sizes that are a great solution for dispensing serums for facial skin care, and this is the same technology used in our Pharma business for derma products. Finally, our FusionPKG team is focused on turnkey beauty solutions and recently provided 13 packaging items for a new line of nourishing facial oil by the indie brand Bad Habit.

In Food + Beverage, our revolutionary SimpliSqueeze elastomeric valve design is one that customers turn to for its wide range of applications and for precise and accurate flow control, and is used on applications within Beauty + Home and Pharma as well. This technology is featured on a new coconut paste in an inverted pouch in India. Additionally, SimpliSqueeze is bringing convenience in flexible packaging, allowing products that have historically been marketed in jars or tubs to be moved to a pouch. The new Jif Squeezy Creamy Peanut Butter and Natural Squeeze Creamy Peanut Butter Spread by Smuckers are great examples of this ongoing conversion of the category. Using the StandCap pouch solution with Aptar's closure, SimpliSqueeze valve and fitment, the package eliminates the need for a knife and brings convenience and ease of use.

During the quarter, we also provided a new custom closure for cappuccino powder in Latin America using our BAP technology, which stands for Aptar's bonded aluminum to plastic patented solution, often used in the food and beverage markets where a secure seal is needed and ease of opening feature added for consumers. The same BAP technology is used by major infant formula brands in North America and is a key technology for the success of Tropicana's orange juice carafe package and for Valvoline's automotive oil package. We continue to be very successful at sharing resources and innovation across our segments, enabling significant economies of scale and a more efficient pathway to market end growth.

A technology that might start in Pharma is often used in our Beauty + Home and Food + Beverage segments as well. We also see many opportunities to leverage our active packaging and material science technology in drug delivery and consumer packaging. Our technical expertise, along with the product, manufacturing and customer synergies we have across our business have made Aptar highly successful in the past, and will continue to strengthen our business model as we look to the future.

Before I turn the call over to Bob, I would like to share a few additional highlights as shown on Slide 7. As we closed out 2020, our steady progress on environmental and social responsibility topics resulted in Aptar achieving the prestigious CDP A List status for our climate changes assessment and Aptar being named a Supplier Engagement Leader. Aptar was also named in the Top 100 of America's Most Responsible Companies by Newsweek and ranked in the top 100 of Barron's Most Sustainable Companies, both for 2021. We were also recognized with Prime Status by ISS ESG, one of the world's leading rating agencies for sustainable investments. Aptar has published new policies around human rights, diversity, equity and inclusion and community engagement and global giving on our website, which outlines our commitment to upholding human rights, the environment and the communities in which we operate.

Finally, we announced earlier this week that we had partnered with CARE, a remarkable organization that works around the globe to save lives, defeat poverty and achieve social justice. Through our global partnership, Aptar will support CARE's education programming, women's economic empowerment efforts and CARE's crisis response campaign, including the Fast and Fair COVID-19 Vaccine Response Campaign.

With that, I will now turn it over to Bob who will provide additional comments on our results. Bob?

Thank you, Stephan, and good morning, everyone. I will walk through some of the details around our fourth quarter performance, starting with Slide 8. In the fourth quarter 2020, reported sales, including positive effects of currency translation rates and recent acquisitions, increased 12% and core sales increased approximately 5%. As Stephan mentioned, our Pharma segment had another outstanding quarter and achieved core sales growth of 10% and an adjusted EBITDA margin of 33%.

Looking at sales growth by market, core sales to the prescription market increased 12% from the prior year. The growth was primarily due to increased sales of our devices for central nervous system medications, certain customers building safety stock levels of inventory in anticipation of potential Brexit-related supply chain concerns and higher tooling sales. Core sales to the consumer health care market increased 2%, mainly due to an increase in tooling sales. Core sales to the injectables market increased 15%, with higher demand for our elastomeric components used with vaccines and other injected medications. Core sales of our active material solutions grew 11%, primarily due to increased demand for our active solutions for probiotics and diabetes applications. Recent articles have mentioned the health benefits of probiotics in the fight against COVID-19, and this, along with new customers in this space, has contributed to our growth.

Turning to our Beauty + Home segment. Core sales decreased 2% and would have been equal with the prior year, had it not been for a decrease in custom tooling sales. Beauty + Home's adjusted EBITDA margin was 11% in the quarter and was negatively impacted by lower sales to the beauty fragrance market. Looking at sales growth by market on a core basis, core sales to the beauty market decreased 15% due to a significant reduction in fragrance, travel and commercial retail sales. Core sales for the personal care market increased 10% due to increased sales of our pumps and closures used on sanitizers, soaps and personal cleansing products. Core sales to the home care market increased 20% due to higher demand for our dispensing systems for household cleaner and disinfectant products.

Turning to our Food + Beverage segment. Core sales increased 13% despite resin pass-through headwinds of 2%. Food + Beverage segment's adjusted EBITDA margin grew to 18% due to a strong mix of products. Looking at each market, core sales to the food market increased 16% due to increased demand for our dispensing solutions used on pantry staples as consumers continue to cook at home during the pandemic. Core sales to the beverage market increased 4% due to increased sales of our closures used on functional drinks and concentrates, which appears to be a restocking effect, as Stephan mentioned, after several quarters of declining volumes.

Turning to Slide 9. Fourth quarter adjusted earnings per share increased 8% to $0.92 per share on a comparable basis with the prior year, including adjusting for currency effects.

Slides 10 and 11 cover our year-to-date performance and I'd like to highlight a few points. Core sales were equal to the prior year despite the challenging year. Adjusted EBITDA decreased slightly, approximately 1%, and this includes a little over $7 million of expense related to a onetime Thank You Award given to employees in the first half of the year in appreciation for their efforts during the pandemic. Adjusted earnings per share decreased 9% to $3.64 per share on a comparable basis with the prior year, including adjusting for currency effects and reflecting the direct and indirect impacts of the pandemic including the Employee Thank You Award.

Slide 12 outlines our outlook for the first quarter. As Stephan discussed, we expect to have a mix effect in Pharma with anticipated strength in our injectables components and active material solutions and weakness in our prescription and consumer health care markets. In addition to the pressure on beauty fragrance business, our Beauty + Home segment is expected to have a negative impact from rising raw material costs. Summing it up, we expect our first quarter adjusted earnings per share range to be $0.86 to $0.94 in the first quarter and this compares to $0.99 per share in the prior year when adjusting for currency effects. While the effects of the severe weather in Texas is still unfolding and we are monitoring raw material costs, it is still too early for us to assess any potential impact.

Turning to Slide 13. I'd like to share a few details around our forecasted capital expenditures for the year and 3 important growth projects that we are excited to get underway and are in addition to our normal capital spending envelope. There are 3 projects that I would like to highlight. First, we've spoken a lot about the recent growth and potential opportunities in our injectables business. This is a very important part of our future and we see Aptar playing a significant role in a stable supply chain for critical injected medicines. We will be pulling forward investments that we had planned to make over the next 5 years and begin to increase our capacity in France and the U.S. Investments we begin to make in 2021 will be completed in 2022 and 2023. The expected cash outlay in 2021 for this phase of our injectables capacity expansion is $35 million.

A second growth investment is being made in a new facility in Suzhou, China that will optimize our footprint and bring all of our existing operations in the Suzhou area under one roof. This investment is predominantly focused on pharma and also includes state-of-the-art machinery and automation for the other segments. This also aligns with our strategy to expand our presence and capabilities in the important fast-growing Chinese market. This will begin in 2021 and be completed in 2022. The expected cash outlay in 2021 for this project is $14 million.

We also are optimizing our footprint and creating a Center of Excellence in France for our highly valued decorative capabilities for the beauty market. We have several facilities that in the recent past, were not operating efficiently and we aim to upgrade our capacity and efficiency under one roof for these activities. This will add to our competitive advantage, and many of our large beauty customers have been very supportive of this decision. This will also begin in 2021 and be completed in 2022. The expected cash outlay in 2021 for this project is $22 million. Including the above roughly $71 million, we are projecting that our 2021 capital expenditures will be in the range of $300 million to $330 million.

At this time, Stephan will provide a few closing comments before we move to Q&A.

Thank you, Bob. In closing, on Slide 14, we had a strong fourth quarter and a good year due to our diversified business, the growth characteristics of our product portfolio and continued investment in technology and innovation. Importantly, our business performed with great resiliency in a very difficult market environment. We generated record cash flow from operations and record free cash flow for the year. As Bob mentioned, we will be making significant growth investments in 2021, while we continue to return capital to shareholders. As a company, we have increased our ESG commitments and received additional recognition by several organizations for our work and efforts to date to make Aptar an even more sustainable, diverse and inclusive company.

Clearly, the recovery from the pandemic and the pace of economic reopening is somewhat delayed compared to what we all thought only 1 quarter ago. The beauty and beverage markets continue to be under pressure and we are experiencing a drawdown of inventories by certain prescription drug and consumer health care customers due to fewer cold and flu illnesses resulting from pandemic-related confinements and fewer noncritical doctor visits. Some customers also built safety stock as they were concerned with potential Brexit-related supply chain disruptions. We expect continued solid growth in our Pharma injectables components, Pharma active material solutions and dispensing systems for sanitizers, cleaners and food products.

Our positive mid and long-term view is unchanged based on our strong innovation and customer project pipelines. In fact, we are encouraged and are taking significant steps to invest in growth capacity and new ways of working that will position us even better in the post-pandemic era. Our balance sheet is in excellent condition, which allows us to take advantage of strategic opportunities. When we raise our sights past this global pandemic-induced crisis, the future is promising, and we look forward to growing each of our businesses for the long-term benefit of all stakeholders.

With that, I would like to open the call up for questions.

(Operator Instructions) Your first question comes from John Kreger with William Blair.

Stephan, can you maybe expand a little bit on your injectable comments? It sounds like you're accelerating some capacity expansion. But do you have room to satisfy some of the COVID-related orders this year before that capacity comes online?

John, yes, thank you. Yes. Indeed, what we're doing in terms of capital expenditure is really pulling forward plans that we had over the next 5 years, anticipating continued growth in this area. We talked previously that we've been very encouraged by customer response to our technical capabilities as everybody was vetted in that proving that the supply chain frenzy. And we are very reasonably optimistic about the future. So we're bringing forward the capital investments. But we have made capital investments only in the years past. So we have the capacity, including research capacity, to fulfill the current requirements. And clearly, in the fourth quarter, roughly 50% of our growth has now been due to COVID-related business and the majority of that is actively supplying the vaccine supply chain.

Great. In your planning process, are you treating the COVID orders as sort of durable and sustainable? Or more of a kind of a one-time bolus that will sort of fade over the next few years?

No, it's really a mix of both. I mean most of our customers have been on the record as have many of the experts that at least for a number of years, this will probably be a recurring seasonal vaccine as the vaccine itself is adapted to new strains. And at the same time, we believe that the recognition of our technical capability bodes well for the broader supply in biotech, large molecule drugs as well as traditional through vaccines and treatments in general that are injected.

Great. And then a quick question on Beauty. Do you think that business can recover before the sort of travel retail patterns get back to normal? Or is this one of these where you probably just have to wait for that to eventually come back?

Well, of course, it's not a homogeneous monolithic business. We have parts of that business that are doing very well. Obviously, everything that has to do with cleaning, sanitizing. And we're encouraged by the growth and comeback already of skin care. Clearly, the luxury fragrance business is very much driven by travel retail and physical retail, and that will indeed have to wait to kind of snap back to the new normal, so to speak. But what we hear from customers, they are starting to gear up for that. Clearly, there has been some encouragement that there was, let's say, a temporary reopening by consumers coming back. China, of course, leads the way, although China is not as large in fragrances at all. But customers expect this to snap back as soon as travel resumes. And certainly, anecdotally, people have pent-up travel intentions now and as soon as they can, travel will resume and that will bode well for that business.

Your next question comes from George Staphos with Bank of America Securities.

Stephan, Bob, Matt. And congratulations on the progress. My question to start is on how you assess your market share and progress given all of the -- I mean it's not a new story at Aptar, it's been the legacy of the company, all of the new products that you bring out quarter by quarter by quarter. Are there any sectors that you would be able to inform investors and analysts on in terms of where you think you're particularly gaining market share or perhaps losing share? And then specifically within injectables, do you think that you're at least getting your market share, if not more, of the COVID vaccine and related products that are in the market or requiring injectable packaging solutions?

Yes. Thanks, George. Starting with the second part of the question, yes, we feel comfortable that we're getting at least our fair share in the injectable space. I've spoken to that previously. In fact, I think the whole pandemic has helped our business in terms of being recognized by customers as technically equivalent to the market leader. And the -- not only the order book, but the inquiries, the project build is very promising. So I feel very confident that we get our fair share, maybe even a bit more than that in the injectable space.

In terms of market share, your larger question, that's a much harder question to answer as our competitive set, it's really quite disposed to each segment and product platform. We are highly encouraged, of course, the progress we are making with our active material solutions. We are highly encouraged with the progress we're making in skin care and moving down the value chain to more rapid turnkey solutions with FusionPKG, which is developing very well. Our pivot to Asia certainly should be faster, if you ask me, but Rome wasn't built on a day, but certainly, more and more of the growth is coming from there. And we are busy with making sure our footprint accommodates that, and we're serving customers where the growth is. Let me leave it there.

Okay. My other question broadly is on margin and profitability near term and then to longer term. So is there a way that you could perhaps quantify what the effect of the destocking and resin impact is in your guidance for the first quarter? And then stretching a bit here, to Beauty + Home, if we didn't have COVID and we hadn't had the transformation benefits coming, do you think this business would have still been about $100 million EBIT business in terms of profit generation? And obviously, the reason I'm asking, at some point, when we do get back to normal, can we look at your past profitability and tack on the roughly $70 million, $80 million and have that to start with? Or has the world changed in your view?

Let me take the second part of the question, and then maybe Bob can address the first part of the question. So we have set out on a big scope for the transformation, and we have even expanded the scope as we went through it. And I'm actually quite happy with what we've accomplished to date, more to do, especially on some of the more footprint rationalization projects. And clearly, COVID was not part of the plan. When we look at the end users that are advantaged by cleaning, sanitizing and so on, the profitability levels are already getting close to the target range. So that -- you don't see that, but that tells me that we have traction on our actions, and we're fully committed to getting this business into the 15% to 17% EBITDA range and then build from there. Clearly, the COVID volume recovery needs to be part of that story.

George, I can take the first part of that question. So as we highlighted, the destocking in the Pharma side is really primarily coming from the prescription division and the CHC division, consumer health care. So those, as you know, are our highest 2 margin divisions within -- inside of Pharma -- in the Pharma segment. So we did bake in a little bit, in fact, amongst the divisions because, again, we still see good growth on injectables and active material solutions. Now the ramp-up in the injectables is -- happens oftentimes in other things, and we saw a little bit in Q4. You end up having some additional cost as the volume starts spiking, right, you have additional overtime, you have some additional expenses that are included there. So we did see in Q4 this year, a little bit of negative effect on the margin in injectables due to some of those additional costs.

And then active packaging, there's also a mix effect within what is sold in the quarter. So we had a little bit of an unfavorable mix effect in Q4. We're not really baking a lot of mix effect into Q1. But I can't give you a specific number in terms of it more directionally.

And then as far as resin goes, we are seeing resin spiking up in Q1, at least in both North America and Europe. So far, we didn't -- we only saw the increase in Q4 coming from North America because it has happened in the past, the euro strengthened considerably against the dollar. So it's somewhat neutralized any increase in resin cost. But we are seeing rising costs for both North America and Europe in Q1. So we did bake in some negative effects on margin there. I will tell you, though, that when we did our estimates, it was still too early to put in any impact that may have come from the storms down in Texas. So we're actively looking at that now and see if that will have any additional impact. But -- so we baked multiples in.

Bob, I mean before storms, $5 million, $10 million, $2 million, just anything to guide us?

Yes, I don't have right at my fingertips exactly what each segment is doing because it's really depending on the pass-through, the volumes in the quarter, which customers. So there's a whole host of additional factors that go in there.

Your next question comes from Ghansham Panjabi with Baird.

So I guess, first off, just sticking with Pharma. I mean there's a lot going on with your various subsegments within that operating unit with the destock you referenced in the first quarter for Rx and OTC, the injectable growth. And then the comparisons you're going to have from really 3 strong years and particularly so last year when there was sort of a stocking effect, if you will, for certain prescription drugs, et cetera. So I guess the question is, as you kind of think about 2021 versus 2020, can you sort of take us through which of these subsegments will actually grow on a year-over-year basis apart from injectables? And I'm just trying to get a sense as to whether we're going to be in a normalization year more broadly for pharmaceuticals in 2021.

Thanks, Ghansham. Overall, we remain very bullish on the Pharma business, and of course, bullish on the company. Clearly, this destocking effect for Rx and CHC, in hindsight, seems obvious, but hindsight is always 20/20. Clearly, the flu season is almost nonexistent. So with all the protective measures people take against COVID, they don't get cold, they don't get flu, they don't get bronchitis. While the -- our customers have been making sure that the trade is stocked, their consumers are stocked and consumers themselves wanting to make sure they have their stuff around. So now that there is no cold and no flu to speak of, this destocking is a logical consequence, but it's transitory. We believe Pharma will continue to grow well for the full year, obviously, more in the second half than in the first half. We continue to look at our 6% to 10% range. And I believe we will be inside that range, maybe at the lower end of that range, but the year is very early. But clearly, we continue to see good growth. Injectables and active material solutions will do very well, but also Rx and CHC will come back.

Okay. Got it. And then for the beauty and fragrance piece, I mean, I think if my notes are correct, you were down 21% in 3Q year-over-year, down 15% in 4Q. A lot of your customers and the suppliers that sell into your customers, IFF and so on and so forth, have actually talked about a normalization higher on a year-over-year basis, starting in 4Q. Just wondering why you haven't seen that? And then can you also clarify the -- your comments about the first quarter not fully seeing the effect from COVID -- first quarter '20 when your comps were still down 8% for that segment from -- based on your numbers?

Yes. So a couple of things. One is, clearly, customers are tasting the recovery so when it comes to customer projects, customer discussions, pipeline planning, there's a lot of optimism in the industry. We have an overexposure to luxury fragrances, which is kind of trailing. Mass fragrance is doing better. Places like Brazil are already growing. But luxury fragrances are still trailing. We see still also good growth in skin care. But again, our overexposure to luxury fragrances is coloring our comments. Sorry, I forgot the second part of your question.

I can answer it.

Yes, go ahead.

Yes, I can answer the second part of the question. So if you remember, Ghansham, back in end of Q3, beginning -- all of Q4 and into Q1, we were in a destocking phase on the personal care side of the business. So beauty was still doing relatively well. So when we got into Q1, it was a little bit normalized, I would say, quarter, right, because we were at the tail end of any destocking on the personal care. So very little effect there. Really, China was the only region that was impacted in Q1 COVID. And there, our size and weight is not so significant. And you also have, every year, the Chinese New Year holiday period. It didn't have that significant impact on our Q1 results. And then as far as the very tail end of March, we did see a weaker finish to the first quarter, primarily in Europe, but it was negligible compared to a full-blown quarter like we saw in Q2 and Q3.

Your next question comes from Mark Wilde with BMO Capital Markets.

Bob, I wonder if you can help us in just thinking about the total capital commitment on those 3 initiatives you outlined. You gave us the number of $71 million for this year, but what does the total look like for all 3 of those projects? And what does that help translate into for sort of a rough thought on where CapEx for the company will be in '22 and '23?

Okay. Great question, Mark. So if I look at the 3 projects, starting with the injectables expansion, we're really looking at a total of about $88 million in total. So a little bit less than half spent in 2021. And then the project will continue for the next couple of years. The China facility, we're going to spend $14 million, as I mentioned. That's about roughly a $40 million, $42 million total investment. And that -- the remainder of that would be spent in 2022. And then the French decorating facility, we're spending about half of that or $22 million in 2021. The total cost is about $44 million, and we should see that completed at the end of 2022. So if you look at the China and the French decorating facility, those are as much, I would say, efficiency, cost savings type of plant consolidations. And then the injectable expansion is really tied to what Stephan was mentioning in terms of the growth in the sector and the need for ongoing vaccines and just general growth in that category. I would expect our normal CapEx to be kind of a net [$240 million, $250 million] range on an annualized basis. And then like we said here, we've addressed these 3 more specific projects.

Which would sit on top of it. So it sounds like your CapEx for '22 is probably in the $300 million, a little over $300 million range. Is that fair?

Yes. Yes, I mean, that's in the ballpark, Mark. And again, I think what we've tried to do is really put an emphasis and a focus on working capital improvements. And I think you've seen that in 2020. We did a terrific job really across all 3, AR, inventory and payables. And we're going to focus again in 2021 and squeeze a little bit more out of that as well to help offset some of that additional increase as much as we can. So we're really focusing, trying to offset some of those extra spend with continued working capital improvements.

Okay. And then for my final one. Stephan, you talked during your presentation about sort of the 5,000 patents of the company. I'm just curious, as you think about expanding in Asia and particularly, as you think about expanding the Pharma business in China, can you just talk generally about protecting intellectual property?

Sure. Look, maybe let me start with -- the last 3 intellectual property challenges we had as a company came from the U.S. and Europe. China has become a lot stronger around protecting intellectual properties and ways to enforcing it. So I would not look at China any differently than any of our other major countries in terms of how we go about filing or protecting trade secrets, compartmentalizing knowledge. So we will and are following the same practices. And no single person has the secret recipe to everything. We document trade secrets and we file for IP no different than we do anywhere else.

(Operator Instructions) Your next question comes from Kyle White with Deutsche Bank.

Wanted to focus a bit on Pharma. First, just kind of a broader top question. We're seeing the rise of telemedicine, which makes prescription drugs looks to be more accessible and widespread to everyone. Is this an opportunity for you? Or are your products not really exposed to the prescription drugs that would be prescribed over telehealth?

Well, I'm more speculating here. I'm not sure that we've got good data, but I found telehealth to be more about maintaining the connection with your GP and rolling over your prescription when it comes to diagnosing new noncritical conditions and actually getting new branded prescriptions, and that is clearly down. So classic, you go to the doctor, the doctor's just being bombarded by pharma salespeople. And all of a sudden, you end up with a new branded prescription that transitions you into a better medicine -- to a more contemporary medicine. That, at least anecdotally, still happens more by in-person visits than at telehealth at the moment. Over time, hopefully, that changes. But clearly, with doctor visits being down, we can see that new branded prescriptions are down.

Yes, that makes sense. I was definitely thinking long term for that. But -- and then also I wanted to focus on the margins in Pharma, your long-term target is the 32% to 36% range. You're at the lower end of that range this quarter. Typically, we've always asked if you need to increase the range. But as you invest in growing injectables, is there a risk that margins might fall below the targeted range longer term?

No. We are committed to this range. There were some onetime items. Bob can talk a bit -- a onetime write-down of an asset in quarter 4 of about $3 million. In addition, we needed some temporary labor in the injectable business to backfill absenteeism from COVID. So there was some onetime margin pressure in Q4, but generally, the 32% to 36% range is the right range.

Your next question comes from Gabe Hajde with Wells Fargo.

Stephan, you made some comments, and I appreciate that you talked about kind of the interdependence of each segment, sharing of technology and manufacturing capabilities. And I also appreciated some of the difficult topics to discuss in a public format. But should we take some of these comments as your view or the company's perspective that Aptar is better off together versus what could be an alternative? Or was there something else you're trying to get across there?

No, not at all. I think we've been over this ground quite a bit. And clearly, we -- Aptar is an integrated business with industrial unit operations that are almost identical, in some cases, shared. We leverage technologies, products, talent and international footprint. So we do precision injection molding, high-speed assembly, metal operations. And of course, we tailor things to different segments. I've used the analogy of jet engines before because in the end we need new devices. GE sells jet engines to airlines to make one price. They sell them to power plant operators, make another price. But the core technology is the same.

So we're not at all interested in any large scale separations to get at the question behind your question. Of course, we will always look at what should we do in-house, what should we outsource, how can we improve the effectiveness of our organization. But it is a coherent industrial business that serves multiple end users. And we move things back and forth, technologies, insights, innovations all the time. When we discuss with customers, we bring the whole portfolio to the table and they often say, hey, this is very interesting what you're doing in beauty, let's try to bring that over to pharma or the other way around.

Well, I appreciate that. And I think to your point, the way you talked about TSR over long periods of time, it's proven successful. And then on the capital allocation or redeployment side, obviously, you have an elevated internal investment cycle, which we actually like to do. Those carry lower risk versus an acquisition-driven expansion. But just curious if that sends a signal or tells us anything as it relates to kind of the acquisition market, whether it's evaluation or just properties available? And then on the share repurchase front, is this something that we should think of as somewhat opportunistic or more programmatic as you guys go throughout the year?

Maybe I should start?

Go ahead.

Yes. Let me start with the last and we'll work our way backwards. So I think one of the things that we've seen over the last several years is even within our CapEx, a stronger portion of our capital is being allocated to Pharma net -- we see that continuing in 2021. So we're -- inside the company for CapEx, we're allocating a larger percentage into the Pharma side.

As it relates to the share repurchase, we generated record cash flow this year at $324 million, and our leverage at the end of the year was 1.6. So we had a pretty significant deleveraging effect. So I think the reason for us lifting the temporary suspension is more due to the fact of our confidence in the cash flow generation and the efforts we've put and made towards working capital reduction. And so we would like to have some optionality there should that continue when our leverage push even lower.

And I'll let Stephan talk about the acquisitions, but as we said many times, even if there's actionable assets that are out there, the timing may not be exactly perfect. So that -- we want that additional piece of optionality there. That's not saying anything or reading into it that we're back in the market actively each quarter. It's just more giving us -- it's indicative more of the confidence that we have in our cash flow generation. Stephan, if you want to mention something about the acquisition?

So look, our M&A machine has never stopped and continues to be active. At the same time, we pride ourselves to be disciplined acquirers, and certainly walk away from more deals than we execute. And for every 1 we execute, we look at 10. But it remains an active M&A environment. It is certainly valuations can be challenging with the debt markets being very wide open. But we will continue to work it. And as we discussed previously, very much like bolt-on acquisitions that complement organic growth. But we are very conscious that, first and foremost, we need to be able to grow our own business and then complement with bolt-ons. And at the same time, we also complement our innovation and prospecting engine with venturing investments, and you've seen us make a few of those. And for the most part, they have proven very successful and always brings something to the company, whether it's a license, whether it's a Board seat, whether it's an ability to increase the stake later on or collaboration agreements. So these venturing investments really give us a front row seat without having to invest fully in each and every area of technology advancement.

Your next question comes from Adam Josephson with KeyBanc.

Bob, would you mind fleshing out the earnings progression comment that you made in the release and presentation? You expect progressive improvement, I know. In a normal year, the first quarter and fourth quarter are typically the lowest just for seasonal reasons. So I'm just wondering how much differently you expect this year to play out than normal? And will those seasonal factors be offset or more than offset by just these different demand patterns that you're expecting this year?

Sure. So I'm not going to give specifics on each quarter-by-quarter because, as you know, we don't give the annual guidance. But if I look at it, you're correct in what you say. What we've seen in the last couple of years, though, is that we have actually seen some higher back end performance than the first half than what is usually, like you said, stronger Q2 and Q3 and then softer Q1 and Q4. We see that trend continuing quite honestly, and it's probably more COVID-related than anything else. So we do see a pretty good bump up in our -- in the way we split the 2021 budget from Q1 to the remainder of the year. So we'll see, obviously, an increase in Q2, but then we'll see a continued increase in Q3. And then Q4, similar to where we're looking at for Q3 right around that ballpark.

And you're talking absolute EPS in that regard, Bob, just to be clear, not the year-over-year?

That's correct. I'm talking absolute.

Yes. Yes. Okay. That's terrific. And Stephan, just back to one of Gabe's question, just about the potential separation of the businesses. And I know you mentioned the industrial logic of keeping these businesses together and the shared technology, et cetera. Can you just talk about -- is the split something you've looked into seriously? And if, in fact, you have -- if there are, in your mind, some advantages to doing so, even though your conclusion is that the industrial logic of having these businesses together is sufficiently powerful that a separation is not worthwhile. I'm just wondering what -- any pros and cons you see from possibly doing that, acknowledging what you said earlier in the call that you don't intend to do so.

Yes. Of course, look, we, on an annual basis, go through a strategic planning exercise. And we review that plan with the Board, including assessment by external advisers. So the Board takes their responsibility very seriously and looks at the valuation of the plan. And it also looks at alternatives, that's the Board responsibility. So we feel very good about that plan and the value creation that we will achieve with that. We're very happy with the investor base we have. Most of them have been stuck for the very much the reason we built our company for the long term, for a long-term compounding and being exposed to the macro trend advantaged end users that generate that long-term growth. And we think there are more investors out there that are interested in. So that's why we also talk to health care investors more and more. We talk to consumer investors more. We're talking to international investors more. And we're talking to ESG-related investors more. But the answer to your question is absolutely that there is -- we believe this is the best plan for shareholders. And most of our long-term holders very much agree with that.

Yes. Just one to follow-up to that, Stephan. Do you think the value in Pharma gets lost to some degree because of the fact that it's combined with this Beauty + Home business that has very, very different characteristics? Or do you not necessarily think that, that's happening?

Well, there is always the short term and the long term. In the short term, multiples and valuations can always be dislocated, but you don't manage a company for what the multiple is at the current moment and what you might do but you build the company for the long term. And over time, the multiple follows as a result. The multiple is not an objective, the multiple is a result of the value you create. In a previous life, I have been in a company that moved from polyolefin to nutrition and the multiple addition was 10 points, but it took 15 years to get that multiple addition. It's a much stronger company and many of the things that made it strong are still there. So it is the long-term compounding nature and the exposure to multiple attractive end users that make the formula within the industrial a coherent operation. So I'm not naive that you could get a short-term pop, but that's not the objective of running the company for the long term.

Our next question comes from Neel Kumar with Morgan Stanley.

In terms of your new injectable capacity in the U.S. and France, could you give us a sense of the magnitude of the increase relative to your current capacity and the potential return? And then in terms of timing, it seems like the project won't be completed until 2022, 2023. Would you characterize the 2-year -- 2- to 3-year duration of project as typical or more extended out than normal?

Well, when you think about Pharma projects, this is very normal. So part of this is the physical build, but that's actually the small part. The -- then the validation of equipment, the validation with customers, the quality systems. The flip side of business being highly differentiated and defensible is there's a lot that goes into not only building but qualifying additional capacity. So this is quite normal.

And then just in terms of the magnitude of the increase?

I'm not sure what you...

Yes. I mean, roughly, we're adding downstream capacity probably in 2 to 3 years, which is about 25% to 30% additional capacity downstream.

Okay. That's helpful. And I'm just wondering if you can just give an update on how the integration of FusionPKG has been progressing relative to your expectations? How has the company been performing in this type of environment?

Yes. As you see from our statement, we're very satisfied with how the FusionPKG team is performing. They have been extremely agile to adjust to the new environment. Customers have been very excited about the combined capability of FusionPKG inside of Aptar, and the linkages and combined offerings we are able to make. So great acquisition and good performance.

Your next question comes from Salvator Tiano with Seaport Global.

Firstly, following up with Neel's question, is there kind of some clarity you can provide with regard to the return on these investments? So if you're investing $71 million this year, and I guess, a good number after that also for the entire project, what's kind of the EBITDA or EBIT benefit you expect to see? And also, can you clarify that comment about the 25% to 30% growth in the next few years? Is that just for, I guess, the injectable segment or for Pharma overall?

Bob, do you want to take that?

Yes. I'll take the last one to start with. So the 25% to 30% additional downstream capacity was specifically for the injectables business, not the other segments at all. And again, injectable components is a multistage process. And so as the volumes increase, there's always additional investments at various stages, whether it's upfront in the mixing capacity or then the finishing and the washing and the drying line. So this is just really kind of adding a total of 25% to 30% capacity for certain components that we manufacture, but does not impact the other Pharma divisions.

Sorry, and on the potential earnings return on these investments?

Sure. I mean -- so it's definitely above where our hurdle rates are. And obviously, being a Pharma investment, it's going to be a pretty good return. But I really don't want to hang my hat on anything right now. But certainly, the projections that we have, it makes all the sense in the world it will be a positive return on investment, much positive.

Okay. And lastly, very quickly on, I guess, the consumer health care and prescription. How do you see things post-COVID? Because it seems like some of the trends with people washing their hands more, potentially wearing masks a little bit more could mute the flu season even after social distancing restrictions are lifted. Is there any chance that we will not see the same -- the pre-COVID demand in a few years, we'll not return there, I guess?

Yes. I think it's too early to speculate on that. We are creatures of habit. And I think people want to get out and mingle again and travel again and that will certainly be a good environment also for colds and flus. Having said that, of course, we have a broader portfolio. Some of the strong growth you saw in quarter 4, it was actually from the CNS category. So overall, we -- and looking at the pipeline we have and customer feedback, we continue to be very bullish on the growth in Pharma. But I think it's fair to say that all the netting off of all the effects of COVID will still take a couple of quarters to sort out until -- once we are in the new environment, a couple of quarters until it all balances out.

Maybe one comment I also wanted to make, many parts of the economy are, of course, gone to full stop. And now that the economy is reopening, hopefully, it's not just a push of a button. There are many things that need to be worked out from basic things like how many shipping containers are available to ship between regions. This is -- there's a lot of dislocation in that area, availability of suppliers. We have been blessed that our operations have kept running. But the larger economy will hit some bumps. You all have followed the chips story with automakers. There will be many more of those stories because you don't just restart an economy that's been paused for 3 quarters and push a button.

Our next question comes from Gabe Hajde with Wells Fargo.

Just one quick one on the competitive landscape in Beauty + Home, maybe more specifically, fragrance. Appreciating that maybe personal care is doing a little bit better because volumes are, in fact, positive. But just we kind of sometimes hear through the trade channels when you have businesses potentially transacting that there can be some disruptive behavior and there's been kind of 2 big deals in the past, I don't know, 36 months or so on the Beauty + Home side. Can you comment at all if you see anything change that just lifts your eyebrow in terms of competitive landscape in that business?

Not really. Assets -- these assets are quite popular with sponsors, and they have changed hands a lot. Sometimes they get absorbed by strategics, which is at least one of the transactions you talked about. But I haven't really seen a change in competitive dynamics, maybe as strategics get involved, it becomes a bit more responsible. But overall, the competitive dynamics have not changed.

All right. I think this is about as much as we can do being over time. And with that, I thank you all for your interest. Looking forward to the virtual interactions to dig into more details. And see you on the next call.

Ladies and gentlemen, this concludes today's conference call. Thank you for participating. You may now disconnect.